IGKV1D-22 and renal fibrosis: In the context of liver and renal fibrosis, MDSCs have been reported to exert anti‐fibrotic effects, potentially through the secretion of IL‐10, which can inhibit fibroblast activation.[20, 37] However, in pulmonary and myocardial fibrosis, MDSCs are implicated in promoting fibrosis through activation of fibroblasts, with S100A8/A9 and TGF‐β1 playing mediating roles.[19, 34] Our study did not identify significant changes in factors known to promote or inhibit fibrosis within MDSCs in intestinal fibrotic tissue.